Fortrea Holdings Inc.

Fortrea NASDAQ: FTRE reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline.

Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.12 per share a year ago.

Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference:

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas Expands Fortrea's early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities Enables more integra…

Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential for a small-cap rebound if the 10-year Treasury yield peaks around their year-end forecast of 5%. I highlight three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000's recent high, defying the index's broader weakness.

Fortrea (NASDAQ: FTRE - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Institutional and Insider Ownership 6.7% of MindWalk shares are

Ausbil Investment Management Ltd trimmed its position in Fortrea Holdings Inc. (NASDAQ: FTRE) by 25.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,704 shares of the company's stock after selling 58,122 shares during the quarter.

Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) reached a new 52-week high during trading on Tuesday. The company traded as high as $21.81 and last traded at $22.1050, with a volume of 16613 shares traded. The stock had previously closed at $21.11. Analysts Set New Price Targets Several equities analysts have recently issued reports

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) has received a consensus rating of "Hold" from the twelve brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1

Fortrea (NASDAQ: FTRE - Get Free Report) and Bullfrog AI (NASDAQ: BFRG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Risk and Volatility Fortrea has a beta of

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.